Research in 2011 regarding β-cell destruction, early immunointervention trials and development of late complications in type 1 diabetes mellitus have highlighted the heterogeneity of this disease. Patient phenotyping should be performed for the implementation of tailored therapies, especially taking into account the age at which the disease is diagnosed.
This is a preview of subscription content, log in via an institution to check access.
References
Bottino, R. et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 53, 2559–2568 (2004).
Tran, P. O et al. Adenoviral overexpression of the glutamylcysteine ligase catalytic subunit protects pancreatic islets against oxidative stress. J. Biol. Chem. 279, 53988–53993 (2004).
Thayer, T. C, et al. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes 60, 2144–2151 (2011).
Orban, T. et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378, 412–419 (2011).
Sherry, N. et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378, 487–497 (2011).
Klinke, D. J. Age-corrected beta cell mass following onset of type 1 diabetes mellitus correlates with plasma C-peptide in humans. PLoS ONE 6, e26873 (2011).
Buzzetti, R. et al. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study. Diabetes 60, 3067–3072 (2011).
Lind, M. et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 378, 140–146 (2011).
Sun, J. K. et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care 34, 968–974 (2011).
Thomas, M. C, et al. Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia 54, 2669–2677 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Andromeda Biotech (consultant, grant/research support), Bristol-Meyers Squibb (speakers bureau), GlaxoSmithKline (grant/research support, speakers bureau), Novartis (speakers bureau), Sanofi-Aventis (speakers bureau).
Rights and permissions
About this article
Cite this article
Pozzilli, P. Heterogeneity of T1DM raises questions for therapy. Nat Rev Endocrinol 8, 78–80 (2012). https://doi.org/10.1038/nrendo.2011.228
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2011.228
- Springer Nature Limited
This article is cited by
-
The effect of spermidine on autoimmunity and beta cell function in NOD mice
Scientific Reports (2022)
-
Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)
Diabetes Therapy (2017)
-
Combination immunotherapies for type 1 diabetes mellitus
Nature Reviews Endocrinology (2015)